Treatment of pyoderma gangrenosum in pregnancy with certolizumab pegol

We report a case of a 41‐year‐old woman who developed pregnancy‐associated pyoderma gangrenosum (PG) at 4 weeks gestation. She was initially treated with prednisone, however, due to lack of improvement and risk of systemic corticosteroids in pregnancy, underwent a prednisone taper and was initiated...

Full description

Saved in:
Bibliographic Details
Published in:JEADV clinical practice 2024-06, Vol.3 (2), p.696-698
Main Authors: Wanberg, Lindsey J., Fletcher, Kathleen M., Goldfarb, Noah, Alavi, Afsaneh
Format: Article
Language:English
Subjects:
biologics
certolizumab pegol
neutrophilic dermatosis
pregnancy
pyoderma gangrenosum
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report a case of a 41‐year‐old woman who developed pregnancy‐associated pyoderma gangrenosum (PG) at 4 weeks gestation. She was initially treated with prednisone, however, due to lack of improvement and risk of systemic corticosteroids in pregnancy, underwent a prednisone taper and was initiated on certolizumab pegol (CZP). The patient experienced complete wound re‐epithelialization 1 month after CZP initiation. She had no pregnancy complications except for prednisone‐associated gestational diabetes and gave birth to a healthy baby. CZP is a tumour necrosis factor‐inhibitor with negligible placental transfer and no known adverse effects in pregnancy. Its efficacy and safety for autoinflammatory dermatoses in pregnancy are very promising. This is the first case to report CZP treatment for PG in a pregnant patient.
ISSN:2768-6566
2768-6566
DOI:10.1002/jvc2.346